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ABSTRACT 
 
Objectives:  
A prospective randomized trial to compare two different durations of maintenance 
immunosuppressive therapy for the prevention of relapse in ANCA-associated 
vasculitis (AAV).  
 
Methods:  
AAV patients were recruited 18-24 months after diagnosis if they were in stable 
remission after cyclophosphamide/prednisolone-based induction followed by 
azathioprine/prednisolone maintenance therapy. They were randomized (1:1) to 
receive continued azathioprine/prednisolone to 48 months from diagnosis 
(continuation group) or to withdraw azathioprine/prednisolone by 24 months 
(withdrawal group). The primary endpoint was the relapse risk, from randomization to 
48 months from diagnosis. 
 
Results:  
One hundred and seventeen patients were randomized and 110 remained to the trial 
end. At entry, median serum creatinine was 116 µmol/l (range 58-372), 53% were 
ANCA positive. The percentage of patients presenting with relapse was higher in the 
withdrawal than in the continuation treatment group (63% vs 22%, p<0.0001, OR 
5.96, 95%CI 2.58-13.77). ANCA positivity at randomization was associated with 
relapse risk (51% vs 29%, p=0.017, OR 2.57, 95%CI 1.16-5.68). Renal function, 
ANCA specificity, vasculitis type and age were not predictive of relapse. Severe 
adverse events were more frequent in the continuation than withdrawal groups (9 vs 
3 events) but the continuation group had better renal outcome (0 vs 4 cases of end 
stage renal disease), with no difference in patient survival.  
 
Conclusions:  
Prolonged remission maintenance therapy with azathioprine/prednisolone, beyond 
24 months after diagnosis, reduces relapse risk out to 48 months and improves renal 
survival in AAV.  
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INTRODUCTION  
 
ANCA-Associated Vasculitides (AAV) are a group of autoimmune systemic diseases 
that are associated with a necrotizing, pauci-immune, vasculitis of small blood 
vessels and the presence of circulating autoantibodies to myeloperoxidase (MPO-
ANCA) or proteinase 3 (PR3-ANCA). The major subgroups of AAV are microscopic 
polyangiitis (MPA), granulomatosis with polyangiitis (GPA, Wegener’s) and 
eosinophilic granulomatosis with polyangiitis (EGPA)[1]. Renal involvement is 
manifested by a necrotizing, crescentic glomerulonephritis and results in end stage 
renal disease (ESRD) in up to 20% of patients[2]. 
Therapeutic management of MPA and GPA is divided into induction and 
maintenance phases. Remission induction is achieved in most cases with 
cyclophosphamide or rituximab in combination with high dose glucocorticoids and 
sometimes plasma exchanges, while remission maintenance regimens have 
employed an oral immunosuppressive, such as azathioprine or methotrexate, or 
repeat dose rituximab, with or without low dose glucocorticoids[3,4]. The optimal 
duration of remission maintenance therapy remains unknown, with current 
consensus recommendations suggesting at least 24 months, once remission has 
been obtained[5].  
Relapse occurs in 30-50% of patients by five years and has been associated with a 
diagnosis of GPA, PR3-ANCA specificity, the presence of ear nose and throat 
involvement, persisting ANCA positivity after induction therapy, a lower serum 
creatinine at diagnosis, and withdrawal of glucocorticoids or immunosuppressives[6]. 
The consequences of relapse are additional accrual of disease and treatment related 
damage and morbidity, and renal relapse is associated with an increased risk of 
ESRD[7]. Continuing remission therapy increases exposure to the toxicities of 
immunosuppressives and glucocorticoids. 
This study tested whether continued azathioprine/prednisolone was more effective in 
preventing relapse than their withdrawal at 24 months from diagnosis in AAV 
patients.  
 
METHODS 
 
Study Design and Patients 
We hypothesized that prolonged maintenance therapy with low-dose prednisolone 
and azathioprine reduces the frequency of relapse, when compared with withdrawal 
of immunosuppression two years after diagnosis. This trial (REMAIN) was conducted 
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by the European Vasculitis Society (EUVAS) and recruited patients from 33 centers, 
in 11 European countries. The study was approved by the local ethics committee in 
each participating center and all patients provided written informed consent, 
according to the Declaration of Helsinki.  
Criteria for inclusion were (1) a diagnosis of MPA, GPA or renal-limited vasculitis. (2) 
Renal involvement and/or other threatened loss of function of a vital organ (lung, 
brain, eye, motor nerve, or gut); and ANCA positivity; ANCA-negative patients were 
eligible for enrollment in the study only when there was histologic confirmation of 
pauci-immune vasculitis. (3) Remission-induction therapy with cyclophosphamide 
and prednisolone for at least 3 months, with or without plasma exchanges. (4) Stable 
remission on azathioprine/prednisolone. They were recruited and randomized 18 to 
24 months from commencement of therapy.  
Exclusion criteria were age under 18, pregnancy, previous malignancy, known HIV 
infection, previous life-threatening relapse, end-stage renal disease (ESRD) at 
inclusion and allergy to study medications. Patients not in stable remission for at 
least six months at 18 months after commencement of therapy and patients who had 
discontinued azathioprine and/or prednisolone were excluded from the study. 
 
Disease definitions 
Diagnostic definitions were initially based on the 1994 Chapel Hill Consensus 
Conference on the Nomenclature of Systemic Vasculitides[8] and re-evaluated after 
completion of the study, according to the recently revised criteria[1]. Remission was 
defined as a 1994 Birmingham Vasculitis Activity Score (BVAS) of 0, indicating the 
absence of new or worse disease activity, with persistent disease activity for no more 
than one item [9]. Major relapse was defined by the recurrence or first appearance of 
at least 1 of the 24 items of the Birmingham Vasculitis Activity Score, that are 
indicative of threatened function of a vital organ (kidney, lung, brain, eye, motor 
nerve, or gut) attributable to active vasculitis. Minor relapse was defined by the 
recurrence or first appearance of at least three other BVAS items. Determinations of 
remission and relapse were made by the investigator and validated retrospectively by 
an independent observer.  
 
Drug regimens 
Patients were randomly assigned at entry, 18 to 24 months after initiation of 
immunosuppression, in a 1:1 ratio, to continuation or withdrawal treatment groups 
(Table 1).  
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Table 1: Drug doses according to treatment arm 
 
Months from 
randomization 
Continuation arm Withdrawal arm 
Prednisolone 
mg/day 
Azathioprine 
mg/kg/day 
Prednisolone 
mg/day 
Azathioprine 
mg/kg/day 
0 5-7.5 1 5 0.75 
1 5-7.5 1 4 0.75 
2 5-7.5 1 4 0.75 
3 5 1 2 0 
4 5 1 1 0 
5 5 1 0 0 
12 5 1 0 0 
18 4 1 0 0 
19 4 1 0 0 
20 3 1 0 0 
21 3 1 0 0 
22 2 1 0 0 
23 1 1 0 0 
24 0 1 0 0 
30 0 1 0 0 
 
 
Evaluations  
Study assessments were performed at entry, then every three months until 30 
months from entry for non-relapsing patients and until the time of relapse for 
relapsing patients. The assessments included BVAS[9], serum creatinine, C-reactive 
protein, ANCA positivity (requiring both positivity by indirect immunofluorescence and 
by PR3-ANCA or MPO-ANCA assay, performed in local laboratories), drug doses 
and adverse events. Glomerular filtration rate (eGFR) was estimated using the 
MDRD formula[10]. All cause damage since the vasculitis diagnosis was assessed 
by the Vasculitis Damage Index (VDI)[11] at entry then every six months to the trial 
end.  
 
End points 
The primary end-point was the percentage of patients presenting a relapse of 
vasculitis, including major and minor relapses, during the study period. Secondary 
end-points were incidence of major and minor relapses, mortality, adverse events of 
therapy, rise in cumulative damage score (VDI), deterioration of eGFR, incidence of 
ESRD and ANCA status during follow-up. 
 
Statistical analysis 
Randomization was performed centrally. Treatment allocation was done by block 
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randomization (permuted blocks of four), per country. Primary data were collected 
locally in record books and subsequently submitted for centralized validation and 
analysis.  
Based on a 1-tailed design, with a significance level of 5% and a power of 0.8, the 
inclusion of 116 patients was required to demonstrate a 20% lower relapse rate in 
the maintenance therapy group during the study period (assuming a 3-fold increase 
of relapse risk in the discontinuation arm).   
The demographic characteristics of the two groups were compared with the use of 
Student’s t-test or a Wilcoxon rank-sum test for continuous measures and a chi-
square test or Fisher’s exact test for categorical variables. The effect of treatment on 
time to relapse was examined by Kaplan–Meier analysis, with the use of the log-rank 
test. The two groups were compared in terms of the secondary end-points reached 
between the time of remission and the end of the study. The rates of adverse events 
were compared with the use of two-by-two tables and Fisher’s exact test. The values 
of eGFR and VDI were compared with the use of the Wilcoxon rank-sum test.  
 
 
RESULTS 
 
Patients 
Between September 1998 and March 2010, 121 patients were enrolled. Four were 
excluded due to ineligibility, because of early relapse (n=3) or malignancy (n=1). One 
hundred and seventeen were randomized with a mean period of 18.8±1.8 months 
after initiation of induction therapy: 61 to the continuation and 56 to the withdrawal 
groups. During the study, three patients withdrew (patient’s choice (n=2) or 
physician’s decision (n=1)) and 4 were lost to follow-up (Figure 1). Complete data for 
analysis were available for 110 patients.  
Demographic characteristics of the study population are detailed in Table 2. Fifty-two 
patients (47%) had GPA and 58 (53%) had MPA. ANCA specificity was PR3 in 52% 
of cases, MPO in 44%, whereas ANCA were negative or without specificity in 4%. 
Almost all patients (96%) were enrolled in this study after the first remission of newly 
diagnosed AAV. The median follow-up was 925 days (IQR 878-970), after 
randomization. 
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Table 2: Demographics of randomized patients according to treatment arm, 18-24 
months after diagnosis 
 
Variable Continuation group 
(n=59) 
Withdrawal group 
(n=51) 
p-Value 
Age (years) 57.7±14.1 57.4±14.3 0.89 
Sex (%)   0.69 
    Male 49 53  
    Female 51 47  
AAV type (%)   0.96 
    GPA 47 47  
    MPA 53 53  
ANCA at diagnosis (%)   0.11 
    PR3 46 59  
    MPO 47 41  
    Negative 7 0  
Delay from diagnosis 
     (months) 
18.6±0.2 19.0±0.2 0.28 
Serum creatinine  
    (µmol/l) 
140±67 129±54 0.34 
eGFR 
    (ml/min/1.73m2) 
51.6±23.0 55.8±23.4 0.34 
ANCA   0.59 
    positive 51% 56%  
    negative 49% 44%  
Prednisolone dose 
 (mg/day) 
5.8±2.3 5.9±2.1 0.61 
Azathioprine dose 
 (mg/day) 
102±35 95±39 0.27 
VDI  1.8±0.2 1.8±0.2 0.98 
 
AAV (ANCA-associated vasculitis), GPA (granulomatosis with polyangiitis), MPA (microscopic 
polyangiitis), PR3 (proteinase 3), MPO (myeloperoxidase), S Creat (serum creatinine), eGFR (estimated 
glomerular filtration rate), VDI (Vasculitis Damage Index). Values are given as means±standard 
deviations. 
 
Protocol treatment 
At randomization, the mean daily azathioprine dose was 99±37 mg and the mean 
daily prednisolone dose was 5.9±2.2 mg. Immunosuppression was rapidly tapered 
according to the study protocol in the withdrawal group, whereas it was continued 
until the end of study in the continuation group. Median and mean daily doses of 
azathioprine and prednisolone are detailed in Supplemental figures 1a and 1b.  
 
Efficacy assessment 
 
Primary end-point 
Thirty-two patients (62.7%) in the withdrawal group experienced a relapse as 
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compared with 13 (22.0%) in the continuation group (log rank test p<0.0001) (Figure 
2a). The patients in the withdrawal group had a 2.84-fold higher relative risk of 
relapse (95%CI 1.72-4.9), when compared to patients continuing 
immunosuppression. Interestingly, 78% of relapses in the withdrawal group occurred 
after removal of azathioprine vs 8% in the continuation group. The median daily 
azathioprine dose at relapse was 75 mg (IQR 50-100) mg in the continuation group 
vs 0 mg (IQR 0-0) in the withdrawal group.  
Of note, primary endpoint difference between treatment groups remained highly 
significant (p<0.001) if we excluded patients of the withdrawal group that continued 
small doses of azathioprine beyond month 6 (n=5) or if we included patients that 
withdrew their consent or were lost to follow-up (n=7).  
 
Secondary end-points 
A major relapse occurred in 18 patients (35.3%) of the withdrawal and in eight 
(13.5%) of the continuation groups (p=0.007) (Figure 2b). The estimated GFR at last 
follow-up was 52.5±26.7 ml/min/1.73m2 in the withdrawal and 54.1±24.7 
ml/min/1.73m2 in the continuation groups (p=0.78). Nevertheless, the ΔeGFR 
between randomization and end of study in the withdrawal group was -3.3±14.9 
ml/min/1.73m2 whereas it was +2.5±9.8 ml/min/1.73m2 in the continuation group 
(p=0.01). This difference was not found when the analysis was restricted to patients 
that had completed follow-up without relapse (+0.8±15.4 vs +2.6±8.0 
ml/min/1.73m2, p=0.53). Four patients (7.8%) of the withdrawal group developed 
ESRD during follow-up as compared with none in the continuation group (p=0.012). 
Of note, median eGFR at randomization, for these 4 patients, was 29.5 
ml/min/1.73m2 (range 15-59). There were two deaths (3.9%) in the withdrawal and 
five (8.5%) in the continuation groups (p=0.32). Causes of death were cancer in 3 
cases, cardiovascular disease in 2, undetermined for 2 patients.  
Although there was no difference in the percentage of ANCA-positive patients at 
randomization (51% in the continuation versus 56% in the withdrawal groups), 
patients in the withdrawal group had more frequent reappearance of ANCA after 
randomization. By month 6, 72% of patients in the withdrawal group were ANCA 
positive compared with 52% in the continuation group (p=0.04) (Supplemental Figure 
2a). There was no difference in the final VDI score between the two groups 
(Supplemental Figure 2b).  
 
Predictors of relapse 
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Univariate analysis revealed that withdrawal of immunosuppression (p<0.0001) and 
ANCA positivity at randomization (p=0.017) were the only predictors of relapse 
during follow-up (Fig 2c, Table 3). Multivariate analysis confirmed these factors were 
independently associated with risk of relapse. ANCA specificity at diagnosis (PR3 vs 
MPO), disease phenotype (GPA vs MPA), age or renal function at randomization, 
were not predictive of relapse in this study. Similar results were obtained when 
studying the risk of major relapse during follow-up.  
 
Table 3: Risk factors associated with AAV relapse 
 
 Subgroup Relapse Risk p-value Odds-ratio (95%CI) 
Treatment arm W 32/51 (63%) <0.0001 5.96 (2.58-13.77) 
C 13/59 (22%) 
ANCA specificity 
at diagnosis 
PR3 28/57 (49%) 0.13 1.82 (0.83-3.98) 
MPO 17/49 (35%) 
ANCA testing at 
randomization 
Positive 30/58 (51%) 0.017 2.57 (1.16-5.68) 
Negative 15/51 (29%) 
Disease MPA 22/58 (38%) 0.5 0.77 (0.36-1.65) 
GPA 23/52 (44%) 
 
AAV (ANCA-associated vasculitis), GPA (granulomatosis with polyangiitis), MPA (microscopic 
polyangiitis), PR3 (proteinase 3), MPO (myeloperoxidase), W (withdrawal subgroup), C (continuation 
subgroup) 
 
Kaplan-Maier analysis shows that the difference between survival according to 
treatment arm persists across different subgroups of patients, such as patients with 
MPO or PR3 ANCA specificity (Supplemental Figure 3a), as well as in patients with 
or without ANCA positivity at randomization (Supplemental Figure 3b).  
 
Severity of relapse 
Characteristics of the relapses occurring during the study period are detailed in 
Suppl. table 1. Relapse severity was not different between treatment arms. Mean 
BVAS at relapse was 7.1±4.1 in the withdrawal group and 8.7±4.4 in the 
continuation group (p=0.29). Organ involvement at relapse was not different between 
the two groups, except ENT involvement, which was more frequent in the 
continuation group (69% vs 34%, p=0.048).   
 
Adverse events 
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Seventy-one adverse events were reported in 46 patients (Table 4). Severe or life-
threatening adverse events occurred in 13 (12%). There was no statistical difference 
between the two groups in the prevalence or severity of adverse events. The most 
frequent events were infections, occurring in 13 (22%) patients of the continuation 
and 10 (19%) of the withdrawal group. Hematological disorders and cardiovascular 
events were more frequent among patients of the continuation group.  
 
Table 4: Adverse events (AE) 
 
Variable Continuation group 
(n=59) 
Withdrawal group 
(n=51) 
p-Value 
Total number of AE 
 
43 28 0.07 
Number (%) of patients with at 
least one AE 
26 (44%) 20 (39%) 0.69 
Number (%) of patients  
with ≥ grade 3 AE 
9 (15%) 3 (6%) 0.13 
Type of AE    
  Cancer 7 4 0.54 
       Non-melanoma skin cancer 2 2 0.99 
  Infection 17 13 0.83 
  Cytopenia 7 1 0.066 
  Hepatitis 2 2 0.99 
  Cardiovascular events 5 0 0.060 
 
Adverse events were classified according to the v3.0 Common Terminology Criteria 
for Adverse Events (CTCAE) 
 
 
DISCUSSION 
 
ANCA-associated vasculitis carries a substantial and often unpredictable risk of 
relapse, and prolonged relapse prevention therapy is recommended that may itself 
contribute to organ damage, morbidity and patient mortality[7]. We have shown that 
continuation of treatment with azathioprine and prednisolone beyond 24 months from 
diagnosis was more effective at preventing relapse than withdrawal of these agents 
for AAV patients with GPA/MPA. These results confirm the ability of the 
azathioprine/prednisolone combination to influence relapse risk and suggest that 
treatment should be continued for at least 48 months from diagnosis, especially in 
those with persistent ANCA positivity after induction therapy. 
 
Despite the use of azathioprine/prednisolone-based remission-maintenance therapy, 
the risk of relapse after induction of remission with cyclophosphamide, was 38% at 5 
years in the recent meta-analysis of previous EUVAS trials[6]. This risk remains high 
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when rituximab is given for induction of remission instead of cyclophosphamide, with 
a 32% risk of relapse at month 18[12]. Previous relapse prevention studies in AAV 
have demonstrated an equivalence of methotrexate to azathioprine, a lower efficacy 
with mycophenolate mofetil, and no efficacy of etanercept[13-15]. In view of the high 
proportion of patients with renal disease in this study, azathioprine was selected over 
methotrexate. Repeat dose rituximab has recently been shown to be superior at 
preventing relapse than azathioprine[16], but this drug was not is use in AAV at the 
time this trial was designed.  
 
The optimal duration of immunosuppressive therapy after induction of remission is 
unknown. Only one previous study has compared different regimens, in patients with 
persistent anti-PR3 ANCA positivity at remission. Sanders et al[17], randomized 45 
patients to receive either standard (1 year after diagnosis and subsequent tapering) 
or extended (4 years after diagnosis and tapered thereafter) azathioprine 
maintenance therapy. Although 46% of patients relapsed in the standard therapy 
group vs 24% in the extended therapy group, the difference was not statistically 
different.  
 
This study clearly demonstrates that continuation of glucocorticoids and azathioprine 
beyond two years is associated with a 3-fold reduction of relapse risk. Moreover, 
extension of immunosuppression is associated with a better renal survival, as 
illustrated by the fact that all patients that reached ESRD during follow-up, had 
discontinued azathioprine a few months before. Of note, previous studies have 
shown that every renal relapse is associated with an eGFR decrease of 8-12 
ml/min[18,19] and that those patients are 4.7 times more likely to progress to 
ESRD[20].  
 
The overall frequency of relapse seen in this study, 41% at 48 months, was similar to 
that reported in other AAV studies (46% in the IMPROVE trial[14], 35% in the 
WEGENT trial[13], 45% in the azathioprine arm of the MAINRITSAN trial)[16]. The 
relapse risk in the withdrawal group of the this study (62.7%) was much higher, but in 
those studies the follow-up period was less than 12 months, after cessation of 
immunosuppression. Interestingly, there was good compliance of clinicians to the 
study drug regimen in the withdrawal group and even a trend to under-dosing in the 
continuation group that may have reduced the magnitude of the treatment effect of 
azathioprine/prednisolone. The relative contributions of azathioprine or prednisolone 
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to the treatment effect are not known, although an earlier systematic review has 
highlighted the increase in relapse risk that follows glucocorticoid withdrawal[6].  
 
In our study, continuation of immunosuppressive therapy was associated with more 
frequent adverse events such as malignancies or infections. The safety profile was 
not statistically different between the two groups, but our study was underpowered to 
detect significant differences in adverse events between groups. Importantly, patient 
survival as well as VDI score - which reflects the cumulative organ damage due to 
vasculitis and/or treatment - was similar. Of note, the final VDI score in the whole 
study population was 2.2, similar to that described (2.66) in the long-term follow-up of 
the EUVAS trials[7]. Despite small numbers, we found that cytopenias and 
cardiovascular complications were more common in the continuation group, possibly 
in relation with the known toxicity of azathioprine and the metabolic effects of 
glucocorticoids.  
 
The main question raised by this study is whether we should recommend an 
extended duration of immunosuppression for all AAV patients after achievement of 
sustained remission. Numerous studies have demonstrated that the risk of relapse is 
more important among patients with GPA and/or anti-PR3[6,21], suggesting that this 
subgroup of patients should receive prolonged immunosuppressive therapy. Our 
study was underpowered to confirm this hypothesis (Supplemental Fig 3a). 
Nevertheless, our data show that persistent ANCA positivity, two years after initiation 
of immunosuppression predicts a higher risk of relapse, suggesting that this 
subgroup of patient may require a different immunosuppressive regimen. Other 
studies have observed a reduced risk of relapse was associated with negativity of 
ANCA at the time of switching to maintenance therapy[22,23]. On the other hand, in 
our study, relapse occurred in 29% of patients with negative ANCAs at 
randomization, when assigned to AZA discontinuation (fig 3b), revealing that even 
those patients have an important risk of relapse when stopping too early the 
immunosuppressive drugs. Of note, 83% of relapsing patients with ANCA negativity 
at inclusion had positive ANCA testing at relapse.  
 
Our study has several limitations. First, this trial was open-label and the absence of 
placebo might have lead to overestimation of the relapse rate in patients having 
discontinued azathioprine and corticosteroids. BVAS is a semi-objective tool 
although many relapses were renal assessed by objective criteria. Nevertheless, 
prognosis was still different between the two groups, even when robust criteria were 
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used to define severe flare of disease or ESRD. Second, this study was designed 
and conducted before widespread use of rituximab and it is difficult to extrapolate 
these results to patients receiving B-cell depleting agents as induction and/or 
maintenance therapy. Further studies are determining if, similarly to what we have 
shown with azathioprine, an 18-months duration is less effective than a 48-months 
maintenance therapy with RTX, for prevention of AAV relapse (MAINRITSAN 3 trail, 
NCT02433522). Third, the study design may have induced some bias in the study 
population, excluding patients with intolerance to azathioprine but also patients with 
more severe disease, such as patients with life-threatening vasculitis or patients that 
experienced early relapse, during the initial 18-months azathioprine therapy 
preceding randomization.  We did not have detailed information from diagnosis to 
precisely describe organ distribution such as ENT or cardiovascular involvement, 
baseline renal function, cyclophosphamide exposure (total dose, i.v./oral 
administration), factors known to influence relapse risk. Four, the 12-years duration 
of study enrollment could have influenced the results. Nevertheless, the relapse rate 
was stable throughout the study period and patients that entered the study before 
2006 had an overall relapse rate of 40% vs 42% for those that were enrolled after 
this date. Finally, we were not able to calculate and compare cumulative 
glucocorticoid dose in each group, as treatment data were not collected for all 
patients, after occurrence of relapse. This point is important as it has been shown 
that part of the long-term metabolic and cardiovascular toxicity of 
immunosuppression is due to excessive cumulative doses of glucocorticoids, given 
either as a preventive remission maintenance therapy or as curative induction 
treatment during repeated flares of AAV [24].  
 
In conclusion, we suggest that at least some of the patients that have reached 
remission of AAV require long-term immunosuppressive therapy to prevent 
recurrence of the disease. The challenge of future studies will be to define the best 
immunosuppressive scheme, providing both efficacy and limited toxicity, but also to 
find clinical or biological markers that will identify high-risk patients who will require 
prolonged therapy.   
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FIGURE LEGENDS 
 
Figure 1:  
Flow diagram of the REMAIN study, summarizing enrolment, intervention allocation, 
follow-up and data analysis.  
 
Figure 2:  
Kaplan-Meier analysis of the study population, showing relapse-free survival 
according to treatment group (2a), major relapse-free survival according to treatment 
group (2b) and relapse-free survival according to positivity or negativity of ANCA at 
randomization (2c). Daily dose of prednisolone and azathioprine in each group is 
shown above.  
 
 
Supplementary figures :  
 
Suppl. Figure1:  
Median and mean doses of azathioprine at each time-point for patients of the 
withdrawal group (1a) and the continuation group (1b).  
 
Suppl. Figure 2: 
ANCA positivity (2a) and vasculitis damage index - VDI (2b) during follow-up 
according to treatment arm.  
 
Suppl. Figure 3: 
Survival without relapse according to treatment arm ,in patients with MPO-ANCA (3a) 
or PR3-ANCA (3b) 
 
Suppl. Figure 4: 
Survival without relapse according to treatment arm, in patients with positive (4a) or 
negative ANCA serology (4b) at randomization 
  
	 16	
REGISTRATION NUMBER OF THE STUDY  
ISRCTN13739474 
 
COMPETING INTERESTS 
-Alexandre Karras has received lecture fees from Roche/Genentech  
-David Jayne has received research grants and lecture fees from Roche/Genentech. 
-Christian Pagnoux has received research grants and lecture fees from 
Roche/Genentech, advisory board fees from ChemoCentryx and Sanofi. 
 
CONTRIBUTORSHIP  
AK contributed to data collection, data analysis and interpretation, manuscript 
preparation and review.  
CP contributed to data generation, collection, analysis and interpretation, manuscript 
preparation and review. 
MH contributed to study design and set-up, data generation, analysis and 
interpretation, manuscript preparation and review. 
KdG contributed to data generation, analysis and interpretation, manuscript 
preparation and review. 
XP contributed to data generation, analysis and interpretation, manuscript 
preparation and review. 
JWCT contributed to data generation, analysis and interpretation, manuscript 
preparation and review. 
MS contributed to study design and set-up, data generation, analysis and 
interpretation, manuscript preparation and review. 
LG contributed to data generation, analysis and interpretation, manuscript 
preparation and review. 
DJ contributed to study design and set-up, data generation and collection, analysis 
and interpretation, manuscript preparation and review. 
 
ACKNOWLEDGMENTS 
We are grateful to all the physicians who participated in this trial: 
A. Bruchfeld, Karolinska, Sweden 
F. Chantrel, Colmar, France 
J. Dadoniene, Vilnius, Lithuania 
A. Ekstrand, Helsinki, Finland 
P. Eriksson, Linkoping, Sweden 
M. Essig, Limoges, France 
A. Fernstrom, Karolinska, Sweden 
J. Floege, Aachen, Germany 
P. Gobert, Avignon, France 
P. Godmer, Vannes, France 
C. Hanrotel-Saliou, Brest, France 
L. Harper, Brimingham, UK 
T. Hauser, Basel, Switzerland 
O. Lidove, Paris, France 
F. Maurier, Metz, France 
A. Mertens, Aachen, Germany  
E. Mirapeix, Barcelona, Spain 
J. Odum, Wolverhampton, UK 
T. Quemeneur, Valenciennes, France 
L.F. Quintana, Barcelona, Spain 
H.D. Rupprecht, Erlangen, Germany 
I. Rychlik, Prague, Czech Republic 
D. Selga, Lund, Sweden 
G. Sterner, Malmö, Sweden 
	 17	
N. Tieule, Nice, France 
P. Vanhille, Valenciennes, France 
P. van Paassen , Maastricht, Netherlands 
K. Verburg, Leiden, Netherlands 
S. Weidner, Munich, Germany 
K. Westman, Lund, Sweden 
 
 
FUNDING  
No specific institutional funding  
 
ETHICAL APPROVAL  
The study was approved by the following Institutional Review Board:  
NHS Executive North West MREC, Gateway House, Piccadilly South, Manchester 
M60 7LP , Reference Number: MREC/00/8/74 
 
DATA SHARING  
All study data are included in this manuscript.  
  
	 18	
 
 
REFERENCES 
 
 
1 Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill 
Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 
2012;65:1–11. 
2 Flossmann O, Berden A, De Groot K, et al. Long-term patient survival in ANCA-
associated vasculitis. Ann Rheum Dis 2011;70:488–94.  
3 Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance 
therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. 
N Engl J Med 2003;349:36–44.  
4 Hilhorst M, van Paassen P, Tervaert JWC, et al. Proteinase 3-ANCA Vasculitis 
versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol 2015;26:2314–27.  
5 Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for 
the management of ANCA-associated vasculitis. Ann Rheum Dis 
2016;75:1583–94.  
6 Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of 
antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 
2012;64:542–8. 
7 Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: 
long-term data from the European vasculitis study group (EUVAS) therapeutic 
trials. Ann Rheum Dis 2015;74:177–84.  
8 Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. 
Proposal of an international consensus conference. Arthritis Rheum 
1994;37:187–92. 
9 Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score 
(BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-78.  
10 Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. 
Modification of Diet in Renal Disease Study Group. Ann Intern Med 
1999;130:461–70. 
11 Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of 
the Vasculitis Damage Index for the standardized clinical assessment of 
damage in the systemic vasculitides. Arthritis Rheum 1997;40:371–80. 
12 Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for 
ANCA-associated vasculitis. N Engl J Med 2013;369:417–27.  
13 Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate 
maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790–
803.  
14 Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for 
	 19	
remission maintenance in antineutrophil cytoplasmic antibody-associated 
vasculitis: a randomized controlled trial. JAMA 2010;304:2381–8.  
15 Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. 
Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 
2005;352:351–61.  
16 Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for 
maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771–80. 
17 Sanders J-SF, de Joode AAE, DeSevaux RG, et al. Extended versus standard 
azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-
neutrophil cytoplasmic antibody-associated vasculitis patients who remain 
cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of 
remission: a randomized clinical trial. Nephrology Dialysis Transplantation 
2016;31:1453–9. 
18 de Joode AAE, Sanders J-SF, Stegeman CA. Renal survival in proteinase 3 and 
myeloperoxidase ANCA-associated systemic vasculitis. Clinical Journal of the 
American Society of Nephrology 2013;8:1709–17.  
19 Slot MC, Tervaert JWC, Franssen CFM, et al. Renal survival and prognostic 
factors in patients with PR3-ANCA associated vasculitis with renal involvement. 
Kidney International 2003;63:670–7.  
20 Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance 
in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann 
Intern Med 2005;143:621–31. 
21    de Joode AAE, Sanders J-SF, Rutgers A, et al. Maintenance therapy in 
antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and 
for how long? Nephrology Dialysis Transplantation 2015;30 Suppl 1:i150–8. 
22 Slot MC, Tervaert JWC, Boomsma MM, et al. Positive classic antineutrophil 
cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy 
associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 
2004;51:269–73. 
23 Wada T, Hara A, Arimura Y, et al. Risk factors associated with relapse in 
Japanese patients with microscopic polyangiitis. The Journal of Rheumatology 
2012;39:545–51.  
24 Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the 
anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from 
the European Vasculitis Study Group trials. Rheumatology 2015;54:471–81.  
 
